Peptic Ulcer Disease
Author:
Top Cited Papers
- 3 December 2024
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA
- Vol. 332 (21) , 1832-1842
Abstract
Importance: In the US, peptic ulcer disease affects 1% of the population and approximately 54 000 patients are admitted to the hospital annually for bleeding peptic ulcers.Observations: Approximately 10% of patients presenting with upper abdominal pain in a primary care setting have a peptic ulcer as the cause of their symptoms. The principal causes of peptic ulcer disease are Helicobacter pylori infection, which affects approximately 42% of patients with peptic ulcer disease, and aspirin or nonsteroidal anti-inflammatory drug (NSAID) use, which are etiologic factors in approximately 36% of people with peptic ulcer disease. Complications of peptic ulcer include bleeding (73% of patients), perforation (9% of patients), and pyloric obstruction (3% of patients). Annually, 10 000 people die of peptic ulcer disease in the US. Endoscopy definitively diagnoses peptic ulcer disease. Acid blockers, such as omeprazole, can heal peptic ulcers in approximately 80% to 100% of patients within 4 weeks, but gastric ulcers larger than 2 cm may require 8 weeks of treatment. Eradication of H pylori decreases peptic ulcer recurrence rates from approximately 50% to 60% to 0% to 2%. Discontinuing NSAIDs heals 95% of ulcers identified on endoscopy and reduces recurrence from 40% to 9%. When discontinuing an NSAID is not desirable, changing the NSAID (eg, from ketorolac to ibuprofen), adding a proton pump inhibitor such as omeprazole or lansoprazole, and eradicating H pylori with treatment such as bismuth, metronidazole, and tetracycline combined with omeprazole can reduce recurrence rates.Conclusions and Relevance: Peptic ulcer disease is associated with increased hospitalization rates and mortality. Acid blocking with proton pump inhibitors, such as omeprazole or lansoprazole, is the primary treatment. Recurrence of ulcers can be prevented by eradicating H pylori if present and discontinuing aspirin or NSAIDs if applicable.Keywords
This publication has 88 references indexed in Scilit:
- Risk of Gastrointestinal Bleeding with Concurrent Use of NSAID and SSRI: A Systematic Review and Network Meta-AnalysisDigestive Diseases and Sciences, 2022
- Aspirin Use to Prevent Cardiovascular Disease and Colorectal CancerJAMA, 2022
- Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive peopleCochrane Database of Systematic Reviews, 2016
- Trends in the use of aspirin and nonsteroidal anti‐inflammatory drugs in the general U.S. populationPharmacoepidemiology and Drug Safety, 2013
- Individual NSAIDs and Upper Gastrointestinal ComplicationsDrug Safety, 2012
- Peptic ulcers after the Great East Japan earthquake and tsunami: possible existence of psychosocial stress ulcers in humansJournal of Gastroenterology, 2012
- Can the Clinical History Distinguish Between Organic and Functional Dyspepsia?JAMA, 2006
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Are Genetic Influences on Peptic Ulcer Dependent or Independent of Genetic Influences for Helicobacter pylori Infection?Archives of internal medicine (1960), 2000
- Sucralfate and ranitidine in the treatment of acute duodenal ulcerThe American Journal of Medicine, 1989